Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a novel phospholipid ether PLE platform technology as a targeted delivery and retention vehicle, Cellectar s compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to capitalize on the unique characteristics of cancer cells to find, treat and follow malignancies in a highly selective way. I CLR is a small molecule, broad spectrum, cancer targeted PET imaging agent. A Phase II trial evaluating I CLR in glioblastoma is expected to be completed in . Additionally multiple, investigator sponsored Phase I/II clinical trials are ongoing across solid tumor indications. I CLR is a small molecule, broad spectrum, cancer targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Data from a Phase Ib dose escalation trial of I CLR in patients with advanced solid tumors is anticipated in the first quarter of . CLR is a preclinical, cancer targeted, non radioactive optical imaging agent for intraoperative tumor margin illumination and non invasive tumor imaging. For additional information please visit www.cellectar.com
Quote | Cellectar Biosciences Inc. (NASDAQ:CLRB)
Last: | $2.39 |
---|---|
Change Percent: | 0.81% |
Open: | $2.45 |
Close: | $2.39 |
High: | $2.45 |
Low: | $2.34 |
Volume: | 264,815 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Cellectar Biosciences Inc. (NASDAQ:CLRB)
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...
Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. FLORHAM PARK, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences,...
Message Board Posts | Cellectar Biosciences Inc. (NASDAQ:CLRB)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CLRB News Article - Cellectar Reports Financial Results for First Quarter 2023 and Pro | whytestocks | investorshangout | 05/04/2023 12:55:45 PM |
whytestocks: $CLRB News Article - Cellectar Biosciences Reports Complete Response in a Relapsed/Refr | whytestocks | investorshangout | 02/28/2023 4:40:48 PM |
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Source:Edgar (US | abracky | investorshub | 12/12/2022 5:44:16 AM |
Look at $PSTV - All the due diligence | The Ultimate Choice | investorshub | 09/06/2022 1:47:38 PM |
whytestocks: $CLRB News Article - Cellectar Reports Financial Results for Second Quarter 2022 | whytestocks | investorshangout | 08/05/2022 5:01:10 PM |
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...
Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. FLORHAM PARK, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences,...
Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, develop...